About Genica Pharmaceuticals
Operator of a reference laboratory dedicated to the development and commercialization of diagnostics and therapeutics for neurological and neurogenetic disorders. Genica offers an extensive selection of testing services and interpretive consultation. The full-service neurology laboratory offers Southern blot, PCR, PFGE, Western blot, biochemical, and ELISA methodologies. The company provides novel, proprietary tests for neurological disorders in nine major areas. For neurological autoimmune diseases, the MAG and GM1 autoantibody tests were introduced to physicians in 1990. In February 1991, Genica began offering autoantibody tests for paraneoplastic syndrome with technology licensed from Sloan-Kettering Cancer Center. In addition to neurogenetic disorders and autoimmune association with peripheral nerve diseases, the company provides state-of-the-art technology for neurological complications of Lyme disease, testing services for the neuromuscular transmission defect known as Myasthenia Gravis and offers the world's first commercially available risk-factor diagnostic for Alzheimer's disease.
Genica Pharmaceuticals Frequently Asked Questions (FAQ)
When was Genica Pharmaceuticals founded?
Genica Pharmaceuticals was founded in 1988.
Where is Genica Pharmaceuticals's headquarters?
Genica Pharmaceuticals's headquarters is located at 377 Plantation Street, Worcester.
What is Genica Pharmaceuticals's latest funding round?
Genica Pharmaceuticals's latest funding round is Acquired.
How much did Genica Pharmaceuticals raise?
Genica Pharmaceuticals raised a total of $4.1M.
Who are the investors of Genica Pharmaceuticals?
Investors of Genica Pharmaceuticals include Aetna, MVP, Oxford Partners and Venca.